Entrada Therapeutics, INC Form 4 insider transactions

Kush Parmar, a Director and 10% owner of Entrada Therapeutics, Inc., reported the sale of common stock by affiliated investment funds, 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., across multiple transactions in late June and early July 2025, executed under a Rule 10b5-1 plan.

Entities affiliated with 5AM Ventures, a significant shareholder and director of Entrada Therapeutics, Inc., have reported the sale of common stock totaling 125,000 shares through pre-arranged Rule 10b5-1 trading plans.

Entrada Therapeutics Director Peter S. Kim filed an amended Form 4 to correct an omission, revealing an additional purchase of 25,000 shares of common stock on May 13, 2024, alongside a previously reported purchase on May 14, 2024.

Kush Parmar, a Director and 10% owner of Entrada Therapeutics, Inc., was granted 19,000 stock options with an exercise price of $7.90 per share.

Entrada Therapeutics, Inc. director Peter S. Kim was granted 19,000 stock options with an exercise price of $7.90, vesting on the earlier of June 11, 2026, or the next annual stockholders' meeting.

Entrada Therapeutics, Inc. Director Mary Thistle was granted 19,000 stock options with an exercise price of $7.90, vesting on the earlier of June 11, 2026, or the next annual stockholders' meeting.

Entrada Therapeutics, Inc. Director Bernhardt G. Zeiher was granted 19,000 stock options with an exercise price of $7.90, vesting over one year or until the next annual meeting of stockholders.

Entrada Therapeutics, Inc. Director Gina Chapman has been granted 19,000 stock options with an exercise price of $7.90 per share, aligning her interests with shareholder value.

Entrada Therapeutics, Inc. Director Maha Radhakrishnan was granted 38,000 stock options with an exercise price of $7.60, vesting over three years.

Kory James Wentworth, CFO of Entrada Therapeutics, exercised stock options and acquired 11,134 shares of common stock at $2.1 per share on April 3, 2025, according to a Form 4 filing.

Kory James Wentworth, CFO of Entrada Therapeutics, sold 1,784 shares of common stock at $10.67 per share on March 17, 2025, under a pre-arranged 10b5-1 trading plan.

CEO Dipal Doshi reports acquisition of restricted stock units and stock options, as well as sales to cover tax obligations.

Chief Financial Officer of Entrada Therapeutics, Kory James Wentworth, reports acquisition of restricted stock units and stock options, as well as a sale of shares to cover tax obligations.

Nathan J Dowden, President & COO of Entrada Therapeutics, reports acquisition of restricted stock units and stock options, as well as a sale of shares to cover tax obligations.

Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics, reports acquisition and disposal of company stock and stock options.

MPM BioVentures 2018, L.P. and related entities sold a total of 44,722 shares of Entrada Therapeutics (TRDA) across two transactions on December 10th and 11th, 2024.

MPM BioVentures and related entities sold a total of 44,722 shares of Entrada Therapeutics (TRDA) across two days, reducing their holdings.

Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, executed multiple stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

An executive at Entrada Therapeutics, Natarajan Sethuraman, sold a total of 15,891 shares of common stock over three days under a pre-arranged 10b5-1 trading plan.

Entrada Therapeutics' President of Research & Development, Natarajan Sethuraman, sold a total of 4,109 shares of common stock under a pre-arranged 10b5-1 trading plan.

Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics, sold shares of common stock between November 4th and November 6th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics, sold 600 shares of common stock at $18 per share on October 16, 2024, under a pre-arranged trading plan.

Nathan Dowden, President & COO of Entrada Therapeutics, sold 847 shares of common stock at $16 per share on September 26, 2024, according to a Form 4 filing.

Entrada Therapeutics' CFO, Kory James Wentworth, sold 3,195 shares of common stock at an average price of $14.971 per share on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Nathan Dowden, President & COO of Entrada Therapeutics, sold shares of common stock on September 6 and September 9, 2024, according to a Form 4 filing.

Natarajan Sethuraman, Chief Scientific Officer of Entrada Therapeutics, sold a portion of his holdings in two transactions on September 6 and September 9, 2024, under a pre-arranged trading plan.

Entrada Therapeutics CEO Dipal Doshi sold shares of common stock between September 3rd and September 5th, 2024, to cover tax obligations arising from the vesting of restricted stock units.

Nathan J. Dowden, President & COO of Entrada Therapeutics, sold shares of common stock between September 3rd and September 5th, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Natarajan Sethuraman, Chief Scientific Officer of Entrada Therapeutics, sold shares of common stock between September 3rd and September 5th, 2024, to cover tax obligations arising from the vesting of restricted stock units.